Response to unsolicited enquiries

PRESS RELEASE

Response to unsolicited enquiries

London, 1 March 2013 - Following the receipt of unsolicited enquiries, Hikma Pharmaceuticals PLC ("Hikma") confirms that it is undertaking a review of strategic options for its Injectables business.Said Darwazah, CEO of Hikma said "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."A further announcement will be made if appropriate.----- ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/ 07776 477 050

Lucinda Henderson, Investor Relations Manager +44 (0)20 7399 2765/ 07818 060 211

FTI Consulting +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million.